Vitrakvi Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Larotrectinib

Indications/Uses

Monotherapy in adult & ped patients w/ solid tumors that display a neurotrophic receptor tyrosine kinase gene fusion w/o known acquired resistance mutation; who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity; & who have no satisfactory treatment options.

Dosage/Direction for Use

Adult 100 mg bd until disease progression or unacceptable toxicity occurs. Ped 100 mg/m² bd until disease progression or unacceptable toxicity occurs. Max: 100 mg/dose. Moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment Reduce starting dose by 50%.

Administration

May be taken with or without food: Cap: Swallow whole, do not open/chew/crush.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EX12 - larotrectinib ; Belongs to the class of other protein kinase inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Vitrakvi cap 100 mg

Packing/Price

1's

Form

Vitrakvi cap 25 mg

Packing/Price

1's

Form

Vitrakvi oral soln 20 mg/mL

Packing/Price

1's

Vitrakvi

larotrectinib

Manufacturer:

Penn Pharmaceutical Services Limited